CL2021000928A1 - Composiciones y métodos para la estimulación ovárica controlada - Google Patents

Composiciones y métodos para la estimulación ovárica controlada

Info

Publication number
CL2021000928A1
CL2021000928A1 CL2021000928A CL2021000928A CL2021000928A1 CL 2021000928 A1 CL2021000928 A1 CL 2021000928A1 CL 2021000928 A CL2021000928 A CL 2021000928A CL 2021000928 A CL2021000928 A CL 2021000928A CL 2021000928 A1 CL2021000928 A1 CL 2021000928A1
Authority
CL
Chile
Prior art keywords
methods
compositions
ovarian stimulation
controlled ovarian
controlled
Prior art date
Application number
CL2021000928A
Other languages
English (en)
Inventor
Lisbeth Helmgaard
Bjarke Mirner Klein
Saez Joan-Carles Arce
Patrick Heiser
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2021000928A1 publication Critical patent/CL2021000928A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen métodos que usan y composiciones que incluyen FSH para su uso en el tratamiento de la infertilidad, en los que la dosis se selecciona basándose en la edad de la paciente para optimizar la eficacia acumulativa y/o reducir el riesgo de OHSS.
CL2021000928A 2018-10-17 2021-04-15 Composiciones y métodos para la estimulación ovárica controlada CL2021000928A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746812P 2018-10-17 2018-10-17
EP18203167 2018-10-29

Publications (1)

Publication Number Publication Date
CL2021000928A1 true CL2021000928A1 (es) 2021-10-22

Family

ID=68344788

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021000928A CL2021000928A1 (es) 2018-10-17 2021-04-15 Composiciones y métodos para la estimulación ovárica controlada
CL2022000779A CL2022000779A1 (es) 2018-10-17 2022-03-29 Composiciones y métodos para la estimulación ovárica controlada (divisional de la solicitud no. 202100928)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022000779A CL2022000779A1 (es) 2018-10-17 2022-03-29 Composiciones y métodos para la estimulación ovárica controlada (divisional de la solicitud no. 202100928)

Country Status (17)

Country Link
US (1) US20210353717A1 (es)
EP (1) EP3866833A1 (es)
JP (1) JP2022505191A (es)
KR (1) KR20210079276A (es)
CN (1) CN112789053A (es)
AU (1) AU2019363279A1 (es)
BR (1) BR112021005019A2 (es)
CA (1) CA3110205A1 (es)
CL (2) CL2021000928A1 (es)
CO (1) CO2021005872A2 (es)
IL (1) IL280750A (es)
JO (1) JOP20210025A1 (es)
MA (1) MA53909A (es)
MX (1) MX2021004383A (es)
PH (1) PH12021550417A1 (es)
SG (1) SG11202102340RA (es)
WO (1) WO2020079127A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272763B2 (en) 2017-09-01 2024-02-01 Ferring Bv The composition for controlled stimulation of the ovary

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022303A2 (en) * 2001-09-12 2003-03-20 Applied Research Systems Ars Holding N.V. Use of hcg and lh in controlled ovarian hyperstimulation
EP1364658A1 (en) * 2002-05-24 2003-11-26 Applied Research Systems ARS Holding N.V. Use of varying ratios of gonadotrophins in controlled ovarian hyperstimulation
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
MA53909A (fr) 2022-01-26
WO2020079127A1 (en) 2020-04-23
PH12021550417A1 (en) 2021-09-20
IL280750A (en) 2021-04-29
TW202027780A (zh) 2020-08-01
CO2021005872A2 (es) 2021-09-20
CL2022000779A1 (es) 2022-11-25
CN112789053A (zh) 2021-05-11
JP2022505191A (ja) 2022-01-14
AU2019363279A1 (en) 2021-03-11
CA3110205A1 (en) 2020-04-23
US20210353717A1 (en) 2021-11-18
SG11202102340RA (en) 2021-05-28
KR20210079276A (ko) 2021-06-29
BR112021005019A2 (pt) 2021-06-08
EP3866833A1 (en) 2021-08-25
MX2021004383A (es) 2021-06-04
JOP20210025A1 (ar) 2021-02-07

Similar Documents

Publication Publication Date Title
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2019002895A1 (es) Inhibidores de pd-1/pd-l1.
PE20200494A1 (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CL2021001027A1 (es) Inhibidores selectivos de rgmc y el uso de los mismos
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
CL2019000846A1 (es) Proteína terapéutica.
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
MX2020003563A (es) Anticuerpo anti-pacap.
BR112018009745A8 (pt) compostos heterocíclicos para o tratamento de doença
CO2021005872A2 (es) Composiciones y métodos para la estimulación ovárica controlada
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2019000600A (es) Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.